Li, Gaopeng <br/><br/>
Synergism of hydroxyapatite nanoparticles and recombinant mutant human tumour necrosis factor-alpha in chemotherapy of multidrug-resistant hepatocellular carcinoma.  [electronic resource] 

 -  Liver international : official journal of the International Association for the Study of the Liver  Apr 2010 
 - 585-92 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1478-3231 
<br/><br/><label>Standard No.: </label>10.1111/j.1478-3231.2009.02113.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Apoptosis--drug effects<br/>Blotting, Western<br/>Carcinoma, Hepatocellular--drug therapy<br/>Cell Line, Tumor<br/>Cell Proliferation--drug effects<br/>Disease Models, Animal<br/>Dose-Response Relationship, Drug<br/>Drug Administration Schedule<br/>Drug Resistance, Multiple<br/>Drug Resistance, Neoplasm<br/>Drug Synergism<br/>Durapatite--pharmacology<br/>Female<br/>Genes, MDR--drug effects<br/>Humans<br/>Liver Neoplasms--drug therapy<br/>Mice<br/>Mice, Inbred BALB C<br/>Multidrug Resistance-Associated Proteins--drug effects<br/>Neoplasms, Experimental--drug therapy<br/>Probability<br/>RNA, Messenger--metabolism<br/>Random Allocation<br/>Reverse Transcriptase Polymerase Chain Reaction<br/>Tumor Necrosis Factor-alpha--pharmacology